Serum osteocalcin concentration in patients with prostatic cancer.
Fifty-four subjects were studied: 36 advanced prostatic adenocarcinoma patients in stage D and 18 normal age-matched male controls. Serum alkaline phosphatase, serum acid phosphatase, plasma osteocalcin, 24-h urinary hydroxyproline excretion, and 24-h whole-body retention of [99mTc]-methylene diphosphonate were measured in all subjects before and 3, 6, and 9 weeks after the start of treatment. Skeletal metastases were identified by radiography and/or [99mTc]-methylene diphosphonate bone scan. The results confirm that acid phosphatase is a significant marker in prostatic cancer; serum alkaline phosphatase may be useful in the evaluation and monitoring of bone metastases but it is not always specific; urinary excretion of hydroxyproline is an index of osteoclastic activity; serum osteocalcin may be considered more specific in the evaluation and monitoring of osteoblastic bone metastases in prostatic cancer.
Francini
G
G
Institute of Medical Semeiotics, University of Siena, Italy.
Bigazzi
S
S
Leone
V
V
Gennari
C
C
D015055:1-Carboxyglutamic Acid / Q000097:blood*; D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D001842:Bone and Bones / Q000032:analysis; D002135:Calcium-Binding Proteins / Q000097:blood*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000652:urine; D015675:Osteocalcin; D011471:Prostatic Neoplasms / Q000097:blood* / Q000652:urine; D011877:Radionuclide Imaging; D014812:Vitamin K / Q000097:blood*
D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins; D015675:Osteocalcin; D014812:Vitamin K; D015055:1-Carboxyglutamic Acid; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D006909:Hydroxyproline